Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA
Table 1
(a) Patients’ initial clinical characteristics as reported by the different trials. (b) Patients’ initial BMI, gender, and aaIPI scores according to the different trials.
(a)
Protocol
R-CHOP
LNH98-5
LNH03-2B
LNH03-6B
patients
IPI
0
0 (0.0%)
7 (3.8%)
1 (0.2%)
8 (0.8%)
1
29 (14.4%)
122 (66.7%)
14 (2.3%)
165 (16.8%)
2
64 (31.7%)
51 (27.9%)
133 (22.2%)
248 (25.2%)
3
78 (38.6%)
3 (1.6%)
201 (33.5%)
282 (28.6%)
4
30 (14.9%)
0 (0.0%)
173 (28.8%)
203 (20.6%)
5
1 (0.5%)
0 (0.0%)
78 (13.0%)
79 (8.0%)
Age-adjusted IPI
0
20 (9.9%)
7 (3.8%)
10 (1.7%)
37 (3.8%)
1
61 (30.2%)
169 (92.3%)
209 (34.8%)
439 (44.6%)
2
87 (43.1%)
7 (3.8%)
276 (46.0%)
370 (37.6%)
3
34 (16.8%)
0 (0.0%)
105 (17.5%)
139 (14.1%)
aaIPI in groups
0-1
81 (40.1%)
176 (96.2%)
219 (36.5%)
476 (48.3%)
>1
121 (59.9%)
7 (3.8%)
381 (63.5%)
509 (51.7%)
Stage
1
0 (0.0%)
28 (15.3%)
10 (1.7%)
38 (3.9%)
2
41 (20.3%)
62 (33.9%)
60 (10.0%)
163 (16.5%)
3
33 (16.3%)
21 (11.5%)
97 (16.2%)
151 (15.3%)
4
128 (63.4%)
72 (39.3%)
433 (72.2%)
633 (64.3%)
PS
0
67 (33.2%)
120 (65.6%)
211 (35.2%)
398 (40.4%)
1
90 (44.6%)
62 (33.9%)
254 (42.3%)
406 (41.2%)
2
45 (22.3%)
1 (0.5%)
130 (21.7%)
176 (17.9%)
3
0 (0.0%)
0 (0.0%)
5 (0.8%)
5 (0.5%)
LDH
>ULV
131 (64.9%)
89 (48.6%)
411 (68.5%)
631 (64.1%)
Normal
71 (35.1%)
94 (51.4%)
189 (31.5%)
354 (35.9%)
Extranodal sites
>1 extra-nodal sites
106 (52.5%)
50 (27.3%)
306 (51.0%)
462 (46.9%)
≤ 1 extra-nodal site
96 (47.5%)
133 (72.7%)
294 (49.0%)
523 (53.1%)
Bone marrow involvement
Not involved
144 (71.3%)
155 (84.7%)
438 (73.0%)
737 (74.8%)
Involved
55 (27.2%)
27 (14.8%)
128 (21.3%)
210 (21.3%)
Not assessed
3 (1.5%)
1 (0.5%)
34 (5.7%)
38 (3.8%)
Mass > 10 cm
Missing
1
1
0
2
No
141 (70.1%)
137 (75.3%)
496 (82.7%)
774 (78.7%)
Yes
60 (29.9%)
45 (24.7%)
104 (17.3%)
209 (21.3%)
B symptoms
No
124 (61.4%)
136 (74.3%)
377 (62.8%)
637 (64.7%)
Yes
78 (38.6%)
47 (25.7%)
223 (37.2%)
348 (35.3%)
Beta2 microglobulin
Missing
35
41
109
185
>ULV
97 (58.1%)
44 (31.0%)
328 (66.8%)
469 (58.6%)
Normal
70 (41.9%)
98 (69.0%)
163 (33.2%)
331 (41.4%)
Albumin
Missing
11
27
64
102
≤35 g/L
78 (40.8%)
28 (17.9%)
183 (34.1%)
289 (32.7%)
>35 g/L
113 (59.2%)
128 (82.1%)
353 (65.9%)
594 (67.3%)
ULV: upper limit value.
(b)
Initial characteristics
Protocol
R-CHOP
LNH98-5
LNH03-2B
LNH03-6B
patients
Gender
Male
92 (45.5%)
109 (59.6%)
332 (55.3%)
533 (54.1%)
Female
110 (54.5%)
74 (40.4%)
268 (44.7%)
452 (45.9%)
Age at diagnosis
Mean (SD)
69.47 (5.58)
44.73 (11.17)
70.07 (5.09)
65.24 (11.89)
Median
69.5
48.0
70.0
68.0
<60 years
1 (0.5%)
183 (100.0%)
1 (0.2%)
185 (18.8%)
≥60 years
201 (99.5%)
0 (0.0%)
599 (99.8%)
800 (81.2%)
Body mass index (kg/m²)
Mean (SD)
25.05 (4.36)
24.67 (4.46)
25.76 (4.50)
25.41 (4.48)
Median
24.5
24.3
25.0
24.8
Min; max
16; 41
16; 39
16; 47
16; 47
<18.5
12 (5.9%)
14 (7.7%)
9 (1.5%)
35 (3.6%)
18.5–25
96 (47.5%)
90 (49.2%)
296 (49.3%)
482 (48.9%)
>25
94 (46.5%)
79 (43.2%)
295 (49.2%)
468 (47.5%)
Gender and BMI in groups
Male—BMI < 18.5
2 (1.0%)
5 (2.7%)
4 (0.7%)
11 (1.1%)
Male—BMI 18.5–25
43 (21.3%)
48 (26.2%)
166 (27.7%)
257 (26.1%)
Male—BMI > 25
47 (23.3%)
56 (30.6%)
162 (27.0%)
265 (26.9%)
Female—BMI < 18.5
10 (5.0%)
9 (4.9%)
5 (0.8%)
24 (2.4%)
Female—BMI 18.5–25
53 (26.2%)
42 (23.0%)
130 (21.7%)
225 (22.8%)
Female—BMI > 25
47 (23.3%)
23 (12.6%)
133 (22.2%)
203 (20.6%)
Age and BMI in groups
Age < 60 years and BMI < 18.5
0 (0.0%)
14 (7.7%)
0 (0.0%)
14 (1.4%)
Age < 60 years and BMI 18.5–25
1 (0.5%)
90 (49.2%)
0 (0.0%)
91 (9.2%)
Age < 60 years and BMI > 25
0 (0.0%)
79 (43.2%)
1 (0.2%)
80 (8.1%)
Age ≥ 60 years and BMI < 18.5
12 (5.9%)
0 (0.0%)
9 (1.5%)
21 (2.1%)
Age ≥ 60 years and BMI 18.5–25
95 (47.0%)
0 (0.0%)
296 (49.3%)
391 (39.7%)
Age ≥ 60 years and BMI > 25
94 (46.5%)
0 (0.0%)
294 (49.0%)
388 (39.4%)
Age and gender in groups
Male <60 years
0 (0.0%)
109 (59.6%)
0 (0.0%)
109 (11.1%)
Female <60 years
1 (0.5%)
74 (40.4%)
1 (0.2%)
76 (7.7%)
Male ≥60 years
92 (45.5%)
0 (0.0%)
332 (55.3%)
424 (43.0%)
Female ≥60 years
109 (54.0%)
0 (0.0%)
267 (44.5%)
376 (38.2%)
When BMI classes were established using 16.5 and 30 as the cut-offs, 6 (0.6%) patients were underweight (BMI < 16.5), 838 (85.21%) exhibited a normal weight (BMI: 16.5–30), and 141 (14.3%) were overweight (BMI > 30).
